To the full analysis
Pediatrix Medical Group stock: growth
MDPediatrix Medical Group reported $1.91B in revenue for fiscal 2025, down 4.9% on the prior year, up 2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
4.6%
per year from 2006 to 2025, per share 5.2%
Earnings (Annual rate)
1.5%
per year from 2006 to 2025, per share 2.1%
Free cash flow (Annual rate)
2.3%
per year from 2006 to 2025, per share 2.9%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 2.0% | −3.7% | 4.6% |
| Revenue per share | 2.1% | −2.7% | 5.2% |
| Earnings | no data | −6.9% | 1.5% |
| Earnings per share | no data | −6.0% | 2.1% |
| Free cash flow | 7.5% | −3.0% | 2.3% |
| Free cash flow per share | 7.6% | −2.0% | 2.9% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $818.55M | $124.47M | $164.4M |
| 2007 | $917.64M | $142.72M | $180.01M |
| 2008 | $1.07B | $169.2M | $165.71M |
| 2009 | $1.29B | $175.8M | $226.43M |
| 2010 | $1.4B | $202.69M | $228.45M |
| 2011 | $1.59B | $218M | $239.69M |
| 2012 | $1.82B | $240.91M | $311.2M |
| 2013 | $2.15B | $280.52M | $389.74M |
| 2014 | $2.44B | $317.28M | $404.58M |
| 2015 | $2.78B | $336.32M | $341.63M |
| 2016 | $3.18B | $324.91M | $404.51M |
| 2017 | $3.46B | $320.37M | $462.07M |
| 2018 | $3.65B | $268.63M | $241.06M |
| 2019 | $1.78B | −$1.5B | $338.44M |
| 2020 | $1.73B | −$796.49M | $175.83M |
| 2021 | $1.91B | $130.96M | $44.49M |
| 2022 | $1.97B | $66.34M | $137.23M |
| 2023 | $1.99B | −$60.41M | $104M |
| 2024 | $2.01B | −$99.07M | $184.55M |
| 2025 | $1.91B | $165.39M | $252.63M |
Revenue by segment
How Pediatrix Medical Group, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Health Care, Patient Service85%
- Hospitals Contracts14%
- Other< 1%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|
| Health Care, Patient Service | $1.48B | $1.64B | $1.69B | $1.72B | $1.72B | $1.63B | 85.2% |
| Hospitals Contracts | $218.5M | $240.02M | $262.93M | $275.68M | $286.68M | $271.13M | 14.2% |
| Other | $34.13M | $29.85M | $20.27M | $0 | $0 | $0 | 0% |
| Total revenue | $1.73B | $1.91B | $1.97B | $1.99B | $2.01B | $1.91B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.